Premium
Investigation of selective JAK 1 inhibitor GSK 2586184 for the treatment of psoriasis in a randomized placebo‐controlled phase II a study
Author(s) -
Ludbrook V.J.,
Hicks K.J.,
Hanrott K.E.,
Patel J.S.,
Binks M.H.,
Wyres M.R.,
Watson J.,
Wilson P.,
Simeoni M.,
Schifano L.A.,
Reich K.,
Griffiths C.E.M.
Publication year - 2016
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.14399
Subject(s) - medicine , placebo , psoriasis area and severity index , psoriasis , adverse effect , cohort , gastroenterology , population , randomized controlled trial , dermatology life quality index , incidence (geometry) , plaque psoriasis , dermatology , pathology , physics , alternative medicine , environmental health , optics
Summary Background GSK 2586184 is a selective oral Janus kinase ( JAK )1 inhibitor being evaluated as a treatment for moderate‐to‐severe plaque‐type psoriasis. Objectives To assess the relationship between dose of GSK 2586184 and clinical response, primarily by the Psoriasis Area Severity Index ( PASI ). Methods Sixty patients with moderate‐to‐severe plaque psoriasis were randomized to cohort A: 100 mg, 200 mg or 400 mg GSK 2586184 twice daily or placebo; and eight were randomized to open‐label cohort B, a small exploratory cohort treated with 400 mg GSK 2586184 twice daily, to explore differential gene expression. Results At week 12, a 75% reduction in PASI ( PASI 75) response rates in the intent‐to‐treat population were 0% in the placebo group compared with 13%, 25% and 57% in the 100 mg, 200 mg and 400 mg GSK 2586184 twice‐daily groups, respectively. Increases in the proportion of PASI 75 responses were seen across all dose levels by week 4. Improvement in itch and quality of life were observed at all doses relative to placebo with the greatest improvement seen in the 400‐mg dose group. Overall, the incidence of adverse events ( AE s) was similar across treatment groups, and no relationship between frequency of AE and GSK 2586184 dose was identified. Differential gene expression was observed in involved and uninvolved skin at baseline and in involved skin after 2 weeks of treatment with GSK 2586184. Conclusions Our study demonstrates that 12 weeks of treatment with GSK 2586184 resulted in clinical improvement and was generally well tolerated in patients with moderate‐to‐severe plaque‐type psoriasis.